Abstract 836
Background
In this retrospective cohort study based in Taiwan, we reported the current epidemiology of patients with multiple myeloma and analyzed the effect of bortezomib-based therapy on clinical outcomes.
Methods
We identified 5726 patients with newly diagnosed multiple myeloma (MM) between 2007 and 2015 in Taiwan. Privileges data from the National Health Institute Research Database was used, as it is made readily available to the public in electronic format for research purposes.
Results
Among them, from January 2007 to October 2011, there were 1116 multiple myeloma patients (control group: bortezomib as non-first-line drug), and there were 4610 multiple myeloma patients from November 2011 to December 2015.The results showed that in the case group the proportion of hospital deaths in the future was 15.73% (702/4464), while the proportion of hospital deaths in the control group was 19.80% (221/1116). The patient with first-line with bone marrow transplantation, the first-line without bone marrow transplantation, the non-first-line with bone marrow transplantation, the probability of hospital death risk was 0.387 times higher than that of the non-first-line without bone marrow transplantation) (P < 0.001) ), 0.681 times (P < 0.001), 0.724 times (P = 0.035).
Conclusions
In conclusion, our study showed that the first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma was better than the non-first line. To provide the most representative data on Bortezomib treatment results of MM patients achievable in Taiwan, we could prospectively collect nationwide data including detailed information. This could not only provide stage-stratified survival and disease-specific survival rates but also help to identify better clinical effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract